Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
OPKO Health, Inc. clinical trials
The registry lists 58 studies whose lead sponsor is OPKO Health, Inc. or one of 2 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the OPKO Health, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to OPKO Health, Inc..
- OPKO Health, Inc.49 studiesSame company
Something wrong?
- OPKO IP Holdings II, Inc.5 studies →Acquired — became part of OPKO Health, Inc., Mar 4, 2013 · source ↗
Something wrong?
- ModeX Therapeutics, An OPKO Health Company4 studies →Acquired — became part of OPKO Health, Inc., May 9, 2022 · source ↗
Something wrong?
Focus areas
Conditions OPKO Health, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 58. Browse all 58 →
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsRecruitingNCT06239194Phase 1/2
Sponsor listed in the registry: ModeX Therapeutics, An OPKO Health Company · First submitted after ModeX Therapeutics became part of OPKO Health, Inc.
- A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.RecruitingNCT07445971Phase 1
Sponsor listed in the registry: ModeX Therapeutics, An OPKO Health Company · First submitted after ModeX Therapeutics became part of OPKO Health, Inc.
- Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH ParticipantsRecruitingNCT07512427Phase 1/2
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsRecruitingNCT07494045Phase 2
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruitingNCT07249905Phase 1/2
Sponsor listed in the registry: ModeX Therapeutics, An OPKO Health Company · First submitted after ModeX Therapeutics became part of OPKO Health, Inc.
- Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced TumorsRecruitingNCT07110584Phase 1/2
Sponsor listed in the registry: ModeX Therapeutics, An OPKO Health Company · First submitted after ModeX Therapeutics became part of OPKO Health, Inc.
- Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDITerminatedNCT03602261Phase 2
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTerminatedNCT05543928Phase 3
- Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT02968004Phase 3
- Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT02500316Phase 2
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
- Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19CompletedNCT04551911Phase 2
- Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D InsufficiencyCompletedNCT03588884Phase 4
- A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone DeficiencyTerminatedNCT01909479Phase 3
- Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)TerminatedNCT03297398Phase 2
- Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyCompletedNCT03874013Phase 3
- Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsCompletedNCT03406377Phase 2
- A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 DiabetesCompletedNCT02119819Phase 2
- A Study of LY2944876 in Healthy Japanese and Non-Japanese ParticipantsTerminatedNCT02188303Phase 1
- A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or BCompletedNCT02418793Phase 1
- Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye PatientsCompletedNCT04063644Not applicable
- Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.CompletedNCT03762408Not applicable
- A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product PresentationsCompletedNCT03810664Phase 1
- Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT01592500Phase 2
- A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without DementiaCompletedNCT01791725Phase 2
- ELND005 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00568776Phase 2
- Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseCompletedNCT01735630Phase 2
- ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's DiseaseCompletedNCT00934050Phase 2
- Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I DisorderTerminatedNCT01674010Phase 2
- A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseTerminatedNCT01766336Phase 2
- A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1CompletedNCT00239148Phase 1
- A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1CompletedNCT00239187Phase 1
- Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and RibavirinCompletedNCT00230854Phase 1
- 4Kscore Using Serum Stored UncentrifugedCompletedNCT04130776
- MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)CompletedNCT01225666Phase 2
- Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese VolunteersCompletedNCT02418767Phase 1
- A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese SubjectsCompletedNCT02692781Phase 1
- MOD-4023 Study in Healthy Male VolunteersCompletedNCT01060722Phase 1
- Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCompletedNCT03660800Phase 1
- A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult MaleCompletedNCT02919800Phase 1
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCompletedNCT02274623Phase 1
- Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL ReconstructionCompletedNCT03355651Not applicable
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedNCT02282813Phase 3
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)CompletedNCT01219855Phase 2/3
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)WithdrawnNCT00557791Phase 3
- Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseCompletedNCT00742716Phase 2
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDTerminatedNCT00499590Phase 3
- Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedNCT00888069Phase 1
Sponsor listed in the registry: OPKO IP Holdings II, Inc. · First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc.
- Safety and Efficacy of Topically Applied CTA018 in Plaque PsoriasisCompletedNCT00384098Phase 2